回复@Andy1Li: 第二个槽点，那篇评论跟汤总一样预设【必须中低收入国家自己生产】，然后强调生产难度超高。后续逻辑专业严丝合缝，只是最初预设不一定成立。

【富国之间分享知识产权与know-how】同样有助于加速疫苗生产。今天看到的加拿大方面新闻：

「Biolyse Pharma, an Ontario-based manufacturer, has been waiting many months to help.

While it's not equipped to make mRNA vaccines, it believes it has the potential to produce up to 20 million doses of a viral-vector vaccine per year — but it needs access to a patent of an already-approved vaccine to do so.

Biolyse asked Johnson & Johnson in March, but the company declined.

The company says the U.S. support for IP waiving is encouraging.」

网页链接//@Andy1Li:回复@汤诗语:感谢您终于正面回答问题！谢谢~

不过这篇评论槽点有点多。豁免 ≠ 放弃。最终谈判具体方案神仙都不知道，但却提前预设好自己想要批判的那个稻草人，痛打一通确实很过瘾…